GlassScriptPhysician profile
Charles Thomas Darragh
NPI 1245676774
$1,701.87
in general payments reported to CMS, 2019-2025
19 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2021: $80.62 · 2022: $246 · 2023: $389 · 2024: $420 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.02 | 2019-2025 | Rinvoq, Skyrizi |
| Organogenesis INC. | $316.21 | 2021-2025 | Puraply, Cygnus Dual, Affinity |
| Janssen Biotech, INC. | $129.08 | 2023 | Tremfya |
| Lilly USA, LLC | $101.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $72.99 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.77 | 2019-2024 | Siliq, Targretin |
| Sun Pharmaceutical Industries INC. | $45.65 | 2024-2025 | |
| Ucb, INC. | $40.67 | 2019-2023 | Bimzelx |
| Incyte Corporation | $38.71 | 2022 | |
| Genentech USA, INC. | $36.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.97 | 2022-2023 | Sotyktu |
| Amgen INC. | $31.85 | 2019 | |
| Merck Sharp & Dohme LLC | $24.01 | 2024 | Keytruda |
| Leo Pharma INC. | $22.88 | 2024 | Adbry |
| Botanix Sb INC | $22.72 | 2025 | Sofdra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $21.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.76 | 2022 | |
| Promius Pharma LLC | $13.92 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Darragh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.